Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.

The Journal of pathology - 1 Jul 2020

Wu Fan, Li Guan-Zhang, Liu Han-Jie, Zhao Zheng, Chai Rui-Chao, Liu Yu-Qing, Jiang Hao-Yu, Zhai You, Feng Yue-Mei, Li Ren-Peng, Zhang Wei

Abstract excerpt

Isocitrate dehydrogenase (IDH) wild-type diffuse lower-grade glioma (LGG) is usually associated with poor outcome, but there have been disputes over its clinical outcome and classification. We present here a robust gene expression-based molecular classification of IDH wild-type diffuse LGG into two subtypes with distinct biological and clinical features. A discovery cohort of 49 IDH wild-type diffuse LGGs from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Cluster Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Neoplasm Grading

Share to Predictive Value of Tests

Share to Reproducibility of Results

Share to Transcriptome

Source

Identifiers

PMID: 32418210
DOI: 10.1002/path.5468

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.PMID 32418210Read ↗

Classification of diffuse lower‐grade glioma based on immunological profilingSemantic proximity Read ↗

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade GliomaSemantic proximity Read ↗

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomasSemantic proximity Read ↗

The Evolving Role of Molecular Markers in the Diagnosis and Management of Diffuse GliomaSemantic proximity Read ↗

DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and developmentSemantic proximity Read ↗

Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis.Semantic proximity Read ↗

IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.Semantic proximity Read ↗

Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.Semantic proximity Read ↗

Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas.Semantic proximity Read ↗

Clinical, histopathological, and molecular features of IDH-wildtype indolent diffuse glioma: comparison with typical glioblastoma.Semantic proximity Read ↗

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.Semantic proximity Read ↗

Leveraging a diverse cell-death patterns-based signature to predict the prognosis of low- grade gliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.